Europe Monoclonal antibodies (mAbs) Biosimilars Market Size, Status and Forecast 2014-2026

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • The Monoclonal antibodies (mAbs) Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.3% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Monoclonal antibodies (mAbs) Biosimilars Market Segmentations:

    By Player:

    • Accord Healthcare

    • Dr. Reddy's Laboratories

    • AET Biotech

    • Celltrion

    • Others

    • Amega Biotech

    • Hospira

    • 3SBio

    • Biocon

    • Allergan

    By Type:

    • Erythropoietin (EPO)

    • Human Growth Hormone (HGH)

    • Granulocyte- Colony Stimulating Factor (G-CSF)

    • Monoclonal Antibody (mAb)

    • Insulin

    • Interferon (IFN)

    • Others

    By End-User:

    • Anti-Cancer

    • Anti-Inflammatory/Autoimmune

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Monoclonal antibodies (mAbs) Biosimilars Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Erythropoietin (EPO) from 2014 to 2026

    • 1.3.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Human Growth Hormone (HGH) from 2014 to 2026

    • 1.3.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Granulocyte- Colony Stimulating Factor (G-CSF) from 2014 to 2026

    • 1.3.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Monoclonal Antibody (mAb) from 2014 to 2026

    • 1.3.5 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Insulin from 2014 to 2026

    • 1.3.6 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Interferon (IFN) from 2014 to 2026

    • 1.3.7 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Anti-Cancer from 2014 to 2026

    • 1.4.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Anti-Inflammatory/Autoimmune from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Monoclonal antibodies (mAbs) Biosimilars Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Monoclonal antibodies (mAbs) Biosimilars by Major Types

      • 3.4.1 Market Size and Growth Rate of Erythropoietin (EPO)

      • 3.4.2 Market Size and Growth Rate of Human Growth Hormone (HGH)

      • 3.4.3 Market Size and Growth Rate of Granulocyte- Colony Stimulating Factor (G-CSF)

      • 3.4.4 Market Size and Growth Rate of Monoclonal Antibody (mAb)

      • 3.4.5 Market Size and Growth Rate of Insulin

      • 3.4.6 Market Size and Growth Rate of Interferon (IFN)

      • 3.4.7 Market Size and Growth Rate of Others

    4 Segmentation of Monoclonal antibodies (mAbs) Biosimilars Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Monoclonal antibodies (mAbs) Biosimilars by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Monoclonal antibodies (mAbs) Biosimilars for Anti-Cancer

      • 4.4.2 Market Size and Growth Rate of Monoclonal antibodies (mAbs) Biosimilars for Anti-Inflammatory/Autoimmune

    5 Market Analysis by Major Regions

    • 5.1 Europe Monoclonal antibodies (mAbs) Biosimilars Production Analysis by Top Regions

    • 5.2 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Analysis by Top Regions

    • 5.3 Europe Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.3 France Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    6 Product Circulation of Monoclonal antibodies (mAbs) Biosimilars Market among Top Countries

    • 6.1 Top 5 Export Countries in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 7.1 Germany Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 7.2 Germany Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    8. UK Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 8.1 UK Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 8.2 UK Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    9. France Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 9.1 France Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 9.2 France Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    10. Italy Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 10.1 Italy Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 10.2 Italy Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    11. Spain Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 11.1 Spain Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 11.2 Spain Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    12. Poland Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 12.1 Poland Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 12.2 Poland Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    13. Russia Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 13.1 Russia Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 13.2 Russia Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    14. Switzerland Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 14.1 Switzerland Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 14.2 Switzerland Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    15. Turkey Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 15.1 Turkey Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 15.2 Turkey Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Top Countries

      • 16.3.1 Denmark Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

      • 16.3.2 Finland Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

      • 16.3.3 Norway Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

      • 16.3.4 Sweden Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

      • 16.3.6 Iceland Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Top Countries

      • 17.3.1 Belgium Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

      • 17.3.2 Netherlands Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

      • 17.3.3 Luxembourg Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Top Countries

      • 18.3.1 Estonia Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

      • 18.3.2 Latvia Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

      • 18.3.3 Lithuania Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Accord Healthcare

      • 19.1.1 Accord Healthcare Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Dr. Reddy's Laboratories

      • 19.2.1 Dr. Reddy's Laboratories Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 AET Biotech

      • 19.3.1 AET Biotech Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Celltrion

      • 19.4.1 Celltrion Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Others

      • 19.5.1 Others Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Amega Biotech

      • 19.6.1 Amega Biotech Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Hospira

      • 19.7.1 Hospira Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 3SBio

      • 19.8.1 3SBio Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Biocon

      • 19.9.1 Biocon Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Allergan

      • 19.10.1 Allergan Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    The List of Tables and Figures (Totals 105 Figures and 153 Tables)

    • Figure Product Picture

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Erythropoietin (EPO) from 2014 to 2026

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Human Growth Hormone (HGH) from 2014 to 2026

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Granulocyte- Colony Stimulating Factor (G-CSF) from 2014 to 2026

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Monoclonal Antibody (mAb) from 2014 to 2026

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Insulin from 2014 to 2026

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Interferon (IFN) from 2014 to 2026

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Anti-Cancer from 2014 to 2026

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Anti-Inflammatory/Autoimmune from 2014 to 2026

    • Figure Germany Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure UK Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure France Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Monoclonal antibodies (mAbs) Biosimilars Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Monoclonal antibodies (mAbs) Biosimilars

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Monoclonal antibodies (mAbs) Biosimilars by Different Types from 2014 to 2026

    • Table Consumption Share of Monoclonal antibodies (mAbs) Biosimilars by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Erythropoietin (EPO)

    • Figure Market Size and Growth Rate of Human Growth Hormone (HGH)

    • Figure Market Size and Growth Rate of Granulocyte- Colony Stimulating Factor (G-CSF)

    • Figure Market Size and Growth Rate of Monoclonal Antibody (mAb)

    • Figure Market Size and Growth Rate of Insulin

    • Figure Market Size and Growth Rate of Interferon (IFN)

    • Figure Market Size and Growth Rate of Others

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Monoclonal antibodies (mAbs) Biosimilars by Different End-Users from 2014 to 2026

    • Table Consumption Share of Monoclonal antibodies (mAbs) Biosimilars by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Anti-Cancer

    • Figure Market Size and Growth Rate of Anti-Inflammatory/Autoimmune

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars Production by Major Regions

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars Production Share by Major Regions

    • Figure Europe Monoclonal antibodies (mAbs) Biosimilars Production Share by Major Countries and Regions in 2014

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars Consumption by Major Regions

    • Table Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Major Regions

    • Table Germany Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table UK Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table France Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Italy Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Spain Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Poland Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Russia Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Switzerland Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Turkey Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Monoclonal antibodies (mAbs) Biosimilars Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Germany Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Germany Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Germany Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table UK Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table UK Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table UK Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table UK Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table France Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table France Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table France Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table France Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Italy Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Italy Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Italy Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Italy Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Spain Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Spain Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Spain Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Spain Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Poland Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Poland Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Poland Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Poland Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Russia Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Russia Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Russia Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Russia Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Switzerland Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Switzerland Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Switzerland Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Turkey Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Turkey Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Turkey Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Monoclonal antibodies (mAbs) Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Accord Healthcare

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Accord Healthcare

    • Figure Sales and Growth Rate Analysis of Accord Healthcare

    • Figure Revenue and Market Share Analysis of Accord Healthcare

    • Table Product and Service Introduction of Accord Healthcare

    • Table Company Profile and Development Status of Dr. Reddy's Laboratories

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dr. Reddy's Laboratories

    • Figure Sales and Growth Rate Analysis of Dr. Reddy's Laboratories

    • Figure Revenue and Market Share Analysis of Dr. Reddy's Laboratories

    • Table Product and Service Introduction of Dr. Reddy's Laboratories

    • Table Company Profile and Development Status of AET Biotech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AET Biotech

    • Figure Sales and Growth Rate Analysis of AET Biotech

    • Figure Revenue and Market Share Analysis of AET Biotech

    • Table Product and Service Introduction of AET Biotech

    • Table Company Profile and Development Status of Celltrion

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Celltrion

    • Figure Sales and Growth Rate Analysis of Celltrion

    • Figure Revenue and Market Share Analysis of Celltrion

    • Table Product and Service Introduction of Celltrion

    • Table Company Profile and Development Status of Others

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Others

    • Figure Sales and Growth Rate Analysis of Others

    • Figure Revenue and Market Share Analysis of Others

    • Table Product and Service Introduction of Others

    • Table Company Profile and Development Status of Amega Biotech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amega Biotech

    • Figure Sales and Growth Rate Analysis of Amega Biotech

    • Figure Revenue and Market Share Analysis of Amega Biotech

    • Table Product and Service Introduction of Amega Biotech

    • Table Company Profile and Development Status of Hospira

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Hospira

    • Figure Sales and Growth Rate Analysis of Hospira

    • Figure Revenue and Market Share Analysis of Hospira

    • Table Product and Service Introduction of Hospira

    • Table Company Profile and Development Status of 3SBio

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of 3SBio

    • Figure Sales and Growth Rate Analysis of 3SBio

    • Figure Revenue and Market Share Analysis of 3SBio

    • Table Product and Service Introduction of 3SBio

    • Table Company Profile and Development Status of Biocon

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biocon

    • Figure Sales and Growth Rate Analysis of Biocon

    • Figure Revenue and Market Share Analysis of Biocon

    • Table Product and Service Introduction of Biocon

    • Table Company Profile and Development Status of Allergan

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan

    • Figure Sales and Growth Rate Analysis of Allergan

    • Figure Revenue and Market Share Analysis of Allergan

    • Table Product and Service Introduction of Allergan

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.